Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy.

Oncoimmunology · 2021 · PMC8158036 · PMID 34104540

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendp = .09so close (0.05 < p ≤ 0.1)

19 The results showed a trend for the upregulation of HLA ligands ( p = .09).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.